Overview and pipeline of MPTs relevant to the prevention of STIs



Healthy timing & spacing of intended pregnancies

- **J**





36 million abortions

on abortions



Reducing unintended pregnancy will have a huge impact on maternal mortality

Sources: DHS Statcompiler, most recent surveys Singh et al, 2014. Adding if Up, Guttmacher Institut ogles (MP1s): Developing interventions to simultaneously prevent STIs, HIV and pregnancy 2015 World STI & HIV Concress & HIV/ADS Conterence

<section-header><section-header><section-header><figure><list-item><list-item><list-item><figure>

Multipurpose Prevention Technologies



purpose Prevention Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy 2015 World STIs HIV Congress & HIV/ADS Contenence 16 September 2015 – Ritiona, sustrial

MPTs: Historical Precedents H2O + flouride The pill + iron Grains + folic acid

Multipurpose Prevention Technologies (MPFs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy 2015 World STI & HIV Congress & HIV/ADS Conference 1 & September 2015 = Risinane, Australia

Who should MPTs target

- Populations at risk for unintended pregnancies, HIV and STIs
 - Young women/ adolescents
 - Sex workers
 - Sexually active women
- Populations at risk for HIV and other STIs
 - MSM
 - Couples intending to conceive

Multipurpose Prevention Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy 2015 World STI & HIV Congress & HIV/ADS Conference 16 Sentember 2015. Brithone, Autorian

Available MPTs: male and female condoms




Multipurpose Prevention Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy 2015 World STI & HIV Congress & HIV/ADS Conference

Available MPTs: SILCS diaphragm



Multipurpose Prevention Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy 2019 World STIs HIV Congress & HIV/ADS Conference 16 Centember 2015, Enthermal Autoritation




What is needed for MPTs to work

- Device needs to be initiated by women rather than men
- Device needs to be acceptable to end users
 - Appearance,
 - ease of use/administration,
 - side effects

Different populations may have different needs

Multipurpose Prevention Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy 2015 World STI & HIV Congress & HIV/ADS Conference 16 Seatometer 2015 – Bittorane. Australia

Regional Providers' Priorities





Multipurpose Prevention Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy 2015 World STIs. HIV Congress & HIV/ADS Conference 16 Sentember 2015. Erkityne, surania

MPTs in the Pipeline

- Longer acting vaginal rings
- Fast dissolving films and tablets
- Innovative and effective gels
- Injectables that combine contraception and infection prevention
- Nanofiber delivery systems




pgles (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregna 2015 World STI & HIV Congress & HIV/AIDS Conference

MPTs in Clinical Trials

| HIV + Other STIs | | |
|--|-----------|--|
| 1.0% Tenofovir Vaginal Gel | Phase III | |
| mapp66 (mAb) Vaginal Film | Phase I | Plus products in |
| MIV-150 + Zinc acetate + Carrageenan Vaginal Gel | Phase I | preclinical |
| Tenofovir + Acyclovir Intravaginal Ring | Phase I | development for: |
| Tenofovir Disoproxil Fumerate Intravaginal Ring | Phase I | • HIV + |
| Tenofovir Vaginal Film | Phase I | Pregnancy |
| Tenofovir Intravaginal | Phase I | HIV + Other STIs |
| Tenofovir Vaginal Tablet | Phase I | Pregnancy, HIV |
| TFV/FTC Vaginal Tablet | Phase I | & Other STIs |
| Pregnancy, HIV & Other STIs | | Pregnancy + Non-HIV STIs |
| Origami Female Condom | Phase III | |
| Tenofovir + Levonorgestrel Intravaginal Ring | Phase I | |

ously prevent STIs, HIV and preg Ies (MPTs): Developing inte 2015 World STI & HIV Congre

Sustained Release Devices: **Combination Intravaginal Rings**



logies (MPTs): Developing interventions to simultaneously preve 2015 World ST & HIV Congress & HIV/AIDS Conference 14 Sentember 2015. Released Australia

Long Acting Injectables: TMC278LA (rilpivirine; PATH; GSK '744 (II; ViiV) HPTN) Injectable nano-suspendence • Experimental integrase inhibitor approved NNRTI • Dose ranging human safety P1 · Long acting: 2-3 mos (?) • NHP model efficacy studies Multiple trials: complete P1 dose ranging PK; SD/MD PK/PD P2 planning ent STIs. HIV and pre les (MPTs): Deve

Single & Multipurpose Vaccines

- Today: Single purpose vaccines (HPV & HBV)
- 20 years: Multivalent vaccines (HSV, HIV, Gonorrhea, Chlamydia, Trichomonas, other STIs)
- Contraceptive vaccines are not likely




tipurpose Prevention Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy 2015 World STI & HIV Congress & HIV/AIDS Conference

Priorities for 1st Generation MPTs



gles (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregna 2015 World STI & HIV Congress & HIV/AIDS Conference

3



MPT Product Development Timeline


Conclusion



Thanks

Anke Hemmerling Kathryn Stewart **Beverley Newman Bethany Young Holt** Helen Rees

logies (MPTs): Developing Interventions to simultaneously prevent STIs, HIV and preg 2015 World STI & HIV Congress & HIV/ADS Conference 16 September 2015 – Brithane, Australia Multipurpose Pre ntion Tech



ogies (MPTs): Developing 2015 World STI & HIV Co 16 September 20

What else is happening in MPT Research & Development?



les (MPTs): Devel